1. Guidance for Industry (2003) Bioavailability and Bioequivalence. Studies for Orally Adminsitered Drug Products-General Considerations. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER)
2. Guidline on the Investigation of Bioequivalence (2010) London: committee for medicinal products for human use (CHMP), European Medicine Agency
3. Annex7 (2006) Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Geneva: World Health Organization
4. Guidance Document-Comparative Bioavailability Standards: Formulations Used for Systemic Effects Canada: Health Canada (2012)
5. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT et al (2009) Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 43(10):1583–97. doi: 10.1345/aph.1M141